好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Completeness and Validation of Automated Reporting to the California Parkinson’s Disease Registry
General Neurology
S21 - Neuroepidemiology (4:18 PM-4:30 PM)
005

To determine completeness and validity of data submitted via automated electronic health record (EHR) interface for the California Parkinson’s Disease Registry (CDPR).

CPDR requires all California clinicians to report patients diagnosed with Parkinson’s disease (PD). To facilitate, an EHR-based algorithm identified PD cases and automatically reported required data to CDPR without user actions.

We manually reviewed 444 randomly selected patients identified based on six PD and parkinsonism ICD10 codes (to compare with two CPDR required codes G20, G90.3), seen at UCLA between 10/1/18 and 12/31/18. Review was conducted by research assistants and supervised by 2 neurologists. Each patient was classified as “Definite PD,” “Possible PD,” or “Not PD” based on documented clinician impression with additional review by neurologists who considered signs, symptoms, treatment responses. For “Definite PD,” we abstracted date of diagnosis as earliest date when PD was documented.

Six ICD10 codes identified 5% more PD cases compared to two CPDR codes. CPDR reported cases had a positive predictive value of 79% for “Definite PD;” 14% cases were “Not PD.” Unexpectedly, we found 25% of “Definite PD” were not reported to CPDR, resulting in 71% sensitivity and 34% specificity. Comparing EHR and abstracted date of diagnosis, 6% of cases matched month-year; 20% cases were within 1 year. The range of date differences was large with 13% being >10 years apart.

Results identified case underreporting, moderate sensitivity and very low specificity for this automated submission to CPDR. Validity of EHR-extracted date of diagnosis was poor and likely depends on EHR implementation and improves with newly diagnosed case selection. CPDR has successfully launched a mandatory state-wide registry for PD with automated EHR interfaces. Iterative and ongoing improvements in interface, algorithm, and workflow designs with validation are required for CPDR to reach its potential as a valid and high-quality population-level PD registry.

Authors/Disclosures
Allan D. Wu, MD, FAAN (Northwestern University)
PRESENTER
An immediate family member of Dr. Wu has received personal compensation in the range of $0-$499 for serving as a Consultant for ClearView Health. Dr. Wu has a non-compensated relationship as a Neuroscience Steering Board with Epic that is relevant to AAN interests or activities. Dr. Wu has a non-compensated relationship as a Subject Matter Expert Panel with Michael J Fox Foundation that is relevant to AAN interests or activities. Dr. Wu has a non-compensated relationship as a Advisory Committee with Parkinson Foundation that is relevant to AAN interests or activities. Dr. Wu has a non-compensated relationship as a Advisory Board with Brain and Life that is relevant to AAN interests or activities. An immediate family member of Dr. Wu has a non-compensated relationship as a Board Member with Illinois State Neurologic Society that is relevant to AAN interests or activities.
Camille Malatt, MD (Cedars-Sinai Movement Disorders) Dr. Malatt has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
No disclosure on file
Caroline M. Tanner, MD, PhD, FAAN (University of California San Francisco, Weill Institute for Neurosciences) Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Evidera. Dr. Tanner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Tanner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz Pharmaceuticals/Cavion. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bial . Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Supernus. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Genentech. The institution of Dr. Tanner has received research support from Gateway LLC. The institution of Dr. Tanner has received research support from Roche\Genentech. The institution of Dr. Tanner has received research support from Michael J Fox Foundation . The institution of Dr. Tanner has received research support from National Institute of Health . The institution of Dr. Tanner has received research support from Department of Defense. Dr. Tanner has received personal compensation in the range of $500-$4,999 for serving as a Faculty, CME presentation with Medscape /WebND.
Eric M. Cheng, MD, MS, FAAN (UCLA) Dr. Cheng has received research support from Dr. Heather Nelson-Brantley.